Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for Treatment of Myeloma Patients Presenting with Extramedullary Disease

Overview / Summary

Study details

Patient eligibility criteria

Newly diagnosed or relapse (patients should have received maximum one line of prior therapy) patients presenting with extramedullary disease of the skin, liver, lungs, central nervous system, lymph nodes or other tissues but not paraskeletal plasmacytoma (expanding soft tissue masses). Detected by physical exam and measured by WBCT/MRI/PET-CT. Documentation of plasma cell infiltration is highly recommended unless it requires invasive surgical intervention such as intracerebral infiltration or plasmacytomas.


No publications connected to this trial at the moment